Board Meeting outcome for Dated May 23, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aspira Pathlab reported Q4 FY26 standalone revenue of ₹652.24 lakhs. For the full year FY26, total income grew 13.5% to ₹2,549.79 lakhs (vs ₹2,238.79 lakhs in FY25), reaching ₹2,498.20 lakhs in revenue from operations. However, profit after tax dropped sharply to ₹5.13 lakhs from ₹207.26 lakhs in FY25, primarily due to a near-doubling of employee benefit expenses to ₹877.68 lakhs and increased finance costs. The auditors issued an unmodified (clean) opinion. The company completed two acquisitions during the year: Aspira DNA Diagnostics Gujarat LLP (slump sale of ₹13 lakhs effective June 30, 2025) and Om Pathology Laboratory, Surat (effective February 1, 2026), resulting in recognised goodwill of ₹330.56 lakhs. As no subsidiary, associate or joint venture of substantive economic significance existed, consolidated financial statements were not prepared. Three key appointments were made: Mrs. Neetu Maurya as Company Secretary and Compliance Officer, M/s. Vishal J Bhanushali & Associates as Internal Auditor, and Mr. Vaibhav Odhekar as Additional Executive Director with extensive tech and cross-border experience.
The 13.5% revenue growth is positive but overshadowed by the dramatic profit decline. Investors should note the elevated cost structure and integration expenses from recent acquisitions. The clean audit opinion and zero debt default are positives. The appointment of a tech-savvy executive director may signal a digital transformation focus going forward.